Skip to main content

Table 4 Life Table representation of cumulative incidence of adjusted therapeutic failure attributable to drug resistance among subjects treated with chloroquine (CQ) and CQ + sulfadoxine/pyrimethamine (SP) with msp-2 genotyping to distinguish recrudescence from reinfection

From: Combined chloroquine, sulfadoxine/pyrimethamine and primaquine against Plasmodium falciparum in Central Java, Indonesia

CQ

CQ+SP

D

N

I

W

IR

CIF

D

N

I

W

IR

CIF

0

26

0

0

0.00

0.00

0

87

0

0

0.00

0.00

2

26

0

0

0.00

0.00

2

87

0

2

0.00

0.00

4

26

0

0

0.00

0.00

4

85

1

1

0.01

0.01

7

26

0

0

0.00

0.00

7

83

0

0

0.00

0.01

11

26

1

0

0.04

0.04

11

83

0

0

0.00

0.01

14

25

1

1

0.04

0.08

14

83

0

0

0.00

0.01

18

23

1

1

0.04

0.12

18

83

0

2

0.00

0.01

21

21

1

2

0.05

0.16

21

81

0

1

0.00

0.01

28

18

3

0

0.17

0.30

28

80

0

2

0.00

0.01

  1. N = sample at risk of therapeutic failure at start of interval
  2. i = the number of cases of therapeutic failure during the interval
  3. w = the number of subjects withdrawn from the test during the interval due to exclusion from analysis, loss to follow-up after latest blood smear, intercurrent infection with another plasmodia species, or reinfection by different genotype P. falciparum or relapse/reinfection by P. vivax based on day of recurrent parasitemia CQ +DCQ concentrations
  4. IR = risk of therapeutic failure in the interval, calculated as i/(N-w/2)
  5. CIF = cumulative incidence of therapeutic failure, calculated as 1-[(1-IRn)(1-CIFn-1)], where IRn is the IR in the current interval and CIFn-1 is the cumulative incidence up to the previous interval